Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 178 participants.

Also called NCT01127269

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 178 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01127269
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Argentina (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01127269. Allocation not applicable; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2013-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
Acronym
AFICIONADO
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
INSULIN GLARGINE
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01127269
Content hash
927ecbe55e4913ea2110642d1a759cfd9b923e43745fed786be01dc0799f18e3